AstaReal Inc. announced the release of AstaREAL® HBA, its new state-of-the-art enhanced bioavailable form of natural astaxanthin. The new high bioavailable product is a water-soluble natural astaxanthin designed for ready-to-drink delivery systems as well as the more traditional form of liquid capsules. With a bioabsorption profile of up to three times greater than a traditional extract oleoresin, AstaREAL HBA provides the tangible benefit of lower use levels.
Joseph Kuncewitch, business manager of AstaReal, said, “Having demonstrated enhanced bio-absorption of astaxanthin by both animal and human study, AstaREAL HBA is ready to provide an opportunity to the market that would broaden the scope of use for this magnificent ingredient.”
AstaReal Inc. is a biotech company within the Fuji Group, exclusively dedicated to the production, research and marketing of natural astaxanthin from the microalgae, Haematococcus pluvialis. AstaREAL is the only astaxanthin that has gone through the successful notification process for GRAS with the FDA.
As the parent company of AstaReal, Fuji has been, for more than 10 years, the world leader in astaxanthin research. To date, there have been 103 published studies on AstaReal astaxanthin that researches health areas such as cardiovascular, skin, eye, muscle, liver function and metabolic health.